Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000297 | 0.79 | MEN1 (0.38) | MEN1CYP3A4CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL29690123 | 0.79 | MEN1 (0.38) | MEN1CYP3A4CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL20768141 | 0.74 | NPC1 (0.48) | MEN1CYP3A4KMT2A | |
| SCHEMBL29357694 | 0.69 | MEN1 (0.37) | MEN1CYP3A4CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL5011110 | 0.69 | MEN1 (0.37) | MEN1CYP3A4CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL1388099 | 0.69 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL1450862 | 0.68 | MAOA (0.33) | MEN1CYP2D6KMT2A | |
| SCHEMBL7467393 | 0.68 | HTR2A (0.38) | MEN1CYP3A4KMT2A | |
| SCHEMBL4436919 | 0.68 | CYP19A1 (0.38) | — | |
| Hydrochloric Acid SCHEMBL11196193 | 0.68 | SIGMAR1 (0.38) | MEN1CYP3A4CYP2D6KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082394-A1 | Tetrahydroisoquinoline Derivatives to Enhance Memory Function | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-03-26 | — | — | US | disclosed |
| EP-1998774-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES TO ENHANCE MEMORY FUNCTION | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007105177-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES TO ENHANCE MEMORY FUNCTION | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082394-A1 | Tetrahydroisoquinoline Derivatives to Enhance Memory Function | GRIN2A, BDNF, GRIN2C | MEN1 2607/4885CYP3A4 2879/4885CYP2D6 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.